Our results will further increase our understanding of the mechanism of action of this tumor promoter, which will strongly validate its candidacy as a potential therapeutic target for combinatorial effects when combined with the current immune checkpoint blockade regimens in patients harboring mutations in either APC or CTNNB1. This evidence concerns the gene CTNNB1 and neoplasm.